News

There’s a sore need to provide more psychological support to people living with Huntington’s disease and their families, not only around the time of testing and potential diagnosis, but throughout the different stages of the disease, according to a study released at the 2024 Huntington’s Disease Society…

The outlook for the Huntington’s disease community has never been brighter, with better care options and promising new research already in progress, the president and CEO of the Huntington’s Disease Society of America said at the organization’s 39th annual convention, taking place in Spokane, Washington. “There has never…

The U.S. Food and Drug Administration (FDA) has authorized new dosage strengths of Austedo XR (deutetrabenazine) extended-release tablets for managing chorea, or involuntary movements, in adults with Huntington’s disease. Teva Pharmaceuticals’ Austedo XR is an extended-release formulation of Austedo (also by Teva) that is meant to…

The 39th annual convention of the Huntington’s Disease Society of America (HDSA) is launching this evening for “three days of education, support and camaraderie!” The convention, which runs from May 30 to June 1, offers many opportunities for attendees to learn about Huntington’s disease and to connect…

Researchers in the U.S. have created the first brain-like organoids, or mini-brains, that incorporate a working blood-brain barrier (BBB), which is the membrane that regulates which circulating substances can reach the brain and spinal cord, and that typically challenges the entry of medications. Called a BBB assembloid, the human model…

Scientists at the Broad Institute of MIT and Harvard have engineered a harmless adeno-associated virus (AAV) that can efficiently reach the brain, potentially improving the efficacy of brain-targeted gene therapies for neurological conditions such as Huntington’s disease. Current AAVs that deliver gene therapies to cells in the body via…

uniQure expects to begin planned discussions with the U.S. Food and Drug Administration (FDA) in the coming months to outline the future steps for testing its gene therapy candidate AMT-130 for early Huntington’s disease, and seeking regulatory approval of the treatment. In its interactions with the FDA, expected to…

Ayana Bio was awarded $300,000 from the National Institutes of Health (NIH) to sample saffron — the world’s most expensive spice — grown in a lab and identify which of its compounds offer the strongest neuroprotective effects for Huntington’s disease. The Boston-based company will use the grant,…

The U.S. Food and Drug Administration (FDA) has approved Neurocrine Biosciences’ oral granules formulation of Ingrezza (valbenazine) — called Ingrezza Sprinkle — for treating chorea, or involuntary movements, in adults with Huntington’s disease. The new formulation, taken once per day, is designed to provide an easier administration option…

May is Huntington’s Disease Awareness Month, and this year the focus is on the patient experience. Huntington’s disease (HD) is a neurodegenerative disorder thought to affect 4.9 per 100,000 people worldwide, including about 41,000 U.S. residents, and can impact many aspects of everyday life. While each patient’s journey…